

A microscopic image of cells, likely cancer cells, is visible in the background. The cells are shown in various stages of division and are characterized by their irregular, textured surfaces. The background is a soft, out-of-focus blue and purple gradient.

BIOVICA

Best possible treatment from day 1

“*Biovica develops and commercializes blood based assays for prognosis and monitoring of effect of targeted cancer treatments*

Our objective is to enable best possible treatment for cancer patients from day one!



Anders Rylander
CEO

Biovica in Brief

- Develops biomarker assays for enabling personalized treatments for better outcome
- Biotech company in early commercial phase
- Listed on First North
- Market Cap ~ SEK 160 m
- Annual turnover of SEK 2.7 m
- Patented technology



Why invest in Biovica?

- Beneficial for cancer patients and payers
- Addresses an unmet need for personalized treatments within metastatic cancer
- Large market potential of SEK 6 billion for metastatic breast cancer area in US & Europe
- Strong scientific collaborations and evidence
- Early commercial phase, next milestone FDA application 2019

More info: <http://biovica.com/investor-relations/analytiker/>



The product DiviTum®

- Measures cell proliferation
- Implemented on standard platform
- Strong competitive position




DiviTum® a blood based biomarker assay

- Blood based
- Monitor and predict treatment response in cancer therapy
- ELISA – standardized platform
- CE-marked
- Patented method and kit



DiviTum[®] provides early response to whether or not the patient's cancer treatment is effective




DiviTum[®] measures cell proliferation rate for faster evaluation of cancer treatment effects

DiviTum[®] - strong position in regards to competing / complementary technologies




Imaging

- Standard method for treatment evaluation
- Requires 3-4 months follow up time
- Example: PET/CT, MRI



Biopsies

- Tumor samples collected through a needle
- Invasive, not suitable for treatment monitoring
- Example: Ki-67 (proliferation marker)



Blood based markers

- Requires only blood sample – convenient for treatment monitoring
- No marker established as golden standard in breast cancer
- Example: CA 15-3 (breast cancer)


Unmet need and market

- First application – metastatic breast cancer (MBC)
- Potential of SEK 6 billion/year in US and Europe alone (MBC)
- Long term potential – standard marker for cancer treatment evaluation





There's an unmet need for biomarkers for individualized cancer treatments

- Many treatment options
- Efficacy evaluation
- Treatment resistance
- Cost issues
- Time consuming diagnostics



Cost for cancer treatments exceeds USD 100 billion!

≥ 90% of new treatments are targeted or hormonals – Biovica focus area




Source: IQVIA Oncology cost report 2018

Biovica focuses primarily on metastatic breast cancer

Breast cancer

- 450 000 patients with metastatic breast cancer in US and Europe
- Market potential SEK 6 billion/year (US & Europe)
- Additional potential: Research market, other metastatic cancers, local cancer, CDx, etc




*) Based on Globocan 2018-data

Strong Clinical Study Results for DiviTum[®]








- 16 articles, peer reviewed and published in oncology journals
- Results within major oncology areas (Breast, Lung, Gastro Intestinal, Blood malignancies)
- Ongoing program within breast cancer with world leading cancer institutes










DiviTum® - Strong evidence within breast cancer



DiviTum® summary of results from published breast cancer studies, all with statistically significant results

	Study	Stage	#Pat	Results
	BRCA	High risk	80	DiviTum able to predict which high-risk-patients (BRCA-positive) that would develop cancer.
	BC early	I,II	161	DiviTum able to predict risk for recurrence within 5 years.
	TEX	III, IV	287	DiviTum prognostic for progression and survival. Better than CA 15-3 (golden standard marker breast cancer).
	Wash-U	II, III	48	DiviTum able to assess changes caused by targeted treatment , 2 weeks after treatment start. Correlated to biopsy proliferation marker.
	Pilot Prato	IV	31	DiviTum able to identify patients responding to hormonal treatment both before and after one month of treatment.
	Lund	IV	142	DiviTum able to identify patients responding to 3 types of treatments both before and during treatment.
	EFFECT	IV	244	DiviTum able to identify patients responding to hormonal treatment (2 nd line) both before and after one month of treatment.
	7 studies	All stages	n=993	

Ongoing metastatic breast cancer study program in collaboration with world-leading institutes


	Study	Stage	#Pat	Endpoints	Status
 BIG Breast International Group	 PYTHIA	IV	120	TK-activity for targeted drug response	2019
 Karolinska Institutet	PREDIX	III	200	TK for targeted drug response and survival	2020
 KU THE UNIVERSITY OF KANSAS	FELINE	III	120	TK for targeted drug response and correlation to other biomarkers	2019
 City of Hope	City of Hope, LA	IV	18	Pilot two targeted drugs, response	2019
 Penn UNIVERSITY OF PENNSYLVANIA	University of Pennsylvania	IV	28	Pilot chemo & targeted drug, response	2019
 JOHNS HOPKINS UNIVERSITY	Johns Hopkins	IV	100	Biomarker for targeted drug resistance	2020
6 studies		III-IV	n=586		

Road to market

- Early commercial phase
- 4 main work flows
 - Clinical development
 - Product development
 - Regulatory approval
 - Market access
- Next milestone: FDA application



Biovica go-to market plan



Team

- Experience of taking biomarker assays and oncology products to market
- Experience of FDA and reimbursement processes
- Committed, a majority of key people are Biovica shareholders



Experienced management team



Anders Rylander
CEO
Holdings: 3 575 640 A-shares
and 360 956 B-shares



Cecilia Driving
CFO
Holdings: 9 000 B-shares
and 40 000 warrants



Pontus Nobreus
Business Dev. Director
Holdings: 6 000 B-shares
20 000 warrants



Adam Germunder
Operations Director
Holdings: 3 600 B-shares and
20 000 warrants



Karin Mattsson, Ph.D
R&D Director
Holdings: 1 000 B-shares
and 40 000 warrants



Mattias Bergqvist
Clinical Dev. Director
Holdings: 106 560 B-shares
and 20 000 warrants



Wing Cheng, Ph.D
Market Access & QA Director
Holdings: 2 500 B-shares
and 20 000 warrants

Board of Directors



Göran Brorsson

Chairman

Holdings: 73 245 A-shares,
116 000 B-shares, 3 000 warrants



Maria Holmlund

Board Member

Holdings: 9 750 B-shares



Jarl Ulf Jungnelius

Board Member

Holdings: 0



Jesper Söderqvist

Board Member

Holdings: 41 085 A-shares,
32 700 B-shares, 3 000 warrants



Anders Rylander

Board Member

Holdings: 3 575 640 A-shares
and 360 956 B-shares

A microscopic view of cells, likely cancer cells, showing their irregular shapes and textures. The cells are rendered in a light, semi-transparent style against a dark blue background with a subtle gradient.

BIOVICA

Best possible treatment from day 1